-
Mar 24,2021
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
-
Feb 23,2021
Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing
-
Feb 1,2021
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
-
Feb 1,2021
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
-
Dec 4,2020
Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates
-
Nov 3,2020
CEPI extends partnership with Clover Biopharmaceuticals to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure
-
Sep 25,2020
Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program
-
Sep 25,2020
Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate
-
Jul 8,2020
CEPI expands partnership with Clover to rapidly advance development and manufacture of COVID-19 vaccine candidate
-
Jun 19,2020
Clover Initiates Phase 1 Clinical Trial for COVID-19 Vaccine Candidate
